Topical Drugs Market (By Type: Semi-solid, Liquid; By Route Of Administration: Dermal, Ophthalmic; By End-use: Burn Centers, Hospitals & Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Topical Drugs Market 

5.1. COVID-19 Landscape: Topical Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Topical Drugs Market, By Type

8.1. Topical Drugs Market, by Type, 2022-2030

8.1.1 Semi-solid formulations

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Liquid Formulations

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Solid Formulations

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Transdermal Products

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Topical Drugs Market, By Route of Administration

9.1. Topical Drugs Market, by Route of Administration, 2022-2030

9.1.1. Dermal Drug Delivery

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Ophthalmic Drug Delivery

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Rectal Drug Delivery

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Vaginal Drug Delivery

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Nasal Drug Delivery

9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Topical Drugs Market, By End-use 

10.1. Topical Drugs Market, by End-use, 2022-2030

10.1.1. Home Care Settings

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Hospitals & Clinics

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Burn Centers

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Other Facilities

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Topical Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.1.3. Market Revenue and Forecast, by End-use (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.1.4.3. Market Revenue and Forecast, by End-use (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.1.5.3. Market Revenue and Forecast, by End-use (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.3. Market Revenue and Forecast, by End-use (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.4.3. Market Revenue and Forecast, by End-use (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.5.3. Market Revenue and Forecast, by End-use (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.6.3. Market Revenue and Forecast, by End-use (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.7.3. Market Revenue and Forecast, by End-use (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.3. Market Revenue and Forecast, by End-use (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.4.3. Market Revenue and Forecast, by End-use (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.5.3. Market Revenue and Forecast, by End-use (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.6.3. Market Revenue and Forecast, by End-use (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.7.3. Market Revenue and Forecast, by End-use (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.3. Market Revenue and Forecast, by End-use (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.4.3. Market Revenue and Forecast, by End-use (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.5.3. Market Revenue and Forecast, by End-use (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.6.3. Market Revenue and Forecast, by End-use (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.7.3. Market Revenue and Forecast, by End-use (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5.3. Market Revenue and Forecast, by End-use (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5.4.3. Market Revenue and Forecast, by End-use (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5.5.3. Market Revenue and Forecast, by End-use (2017-2030)

Chapter 12. Company Profiles

12.1. Bayer AG

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Cipla Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. GSK Group of Companies

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Johnson & Johnson Private Ltd.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Novartis AG

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bausch Health Companies Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Hisamitsu Pharmaceuticals Co. Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Merck & Co., Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Glenmark Pharmaceuticals Ltd.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. MedPharm Ltd.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms